RxDoctor Payments Data

Ada Santiago-Carrion

Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1851881544

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 358 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations.

$10,685in general payments, 2019–2025

Across 358 payments — averaging $29.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Boehringer Ingelheim$1K
  • Sanofi-aventis U.S. LLC$1K
  • Novo Nordisk$1K
  • Dexcom, Inc.$711
  • AstraZeneca$662
  • plus $5K from 15 others

What the payments were for

  • Travel & lodging$330%
  • Food & beverage$10,652100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)30$1,289
Boehringer Ingelheim33$1,263
Sanofi-aventis U.S. LLC29$1,228
Novo Nordisk49$1,003
Dexcom, Inc.23$711
AstraZeneca23$662
Bayer11$639
Eli Lilly Export S.A. Puerto Rico Branch27$556
Bayer Puerto Rico Inc.23$528
Abbott37$502
Medtronic7$433
Novartis9$326
Lilly USA, LLC3$318
Merck16$316
PBG Puerto Rico LLC14$262
Corcept Therapeutics9$216
Johnson & Johnson6$128
AbbVie4$98
Rhythm Pharmaceuticals, Inc.2$86
Perspectum Diagnostics Ltd1$73
Radius Health, Inc.2$49

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,685 in reported general payments places this provider in the 75th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$10,709
Medicare patients
33
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide304$310,839
MounjaroTirzepatide168$181,161
TrulicityDulaglutide159$158,292
Trijardy XrEmpaglifloz/Linaglip/Metformin78$59,742
Synjardy XrEmpagliflozin/Metformin Hcl50$40,458
FarxigaDapagliflozin Propanediol51$39,778
Xigduo XrDapaglifloz Propaned/Metformin28$26,055
RybelsusSemaglutide14$25,215
GlyxambiEmpagliflozin/Linagliptin13$17,306
JardianceEmpagliflozin19$16,623
SynthroidLevothyroxine Sodium98$11,681
HumalogInsulin Lispro56$10,649
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$6,317
Repatha SureclickEvolocumab11$6,271
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$318$350,102383 claims
Novo NordiskOzempic, Rybelsus$1,003$336,054318 claims
Boehringer IngelheimTrijardy Xr, Synjardy Xr, Glyxambi, Jardiance$1,263$134,129160 claims
AstraZenecaFarxiga$662$39,77851 claims
AbbVieSynthroid$98$11,68198 claims
Sanofi-aventis U.S. LLCLantus$1,228$3,63643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →